SCHEMBL3064528

SCHEMBL3064528

Fc1ccc(-c2nc3nc(-c4ccncc4)c(-c4cccnc4)nc3[nH]2)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 15/20 0.53
MAPK13 O15264 13/20 0.53
GCGR P47871 13/20 0.53
MAPK12 P53778 13/20 0.53
MAPK11 Q15759 13/20 0.53
ALOX5 P09917 7/20 0.53
PRKD3 O94806 3/20 0.51
MAP4K4 O95819 3/20 0.51
FRK P42685 3/20 0.51
MAPK9 P45984 3/20 0.51
CSNK1A1 P48729 3/20 0.51
CSNK1D P48730 3/20 0.51
GSK3B P49841 3/20 0.51
CLK4 Q9HAZ1 3/20 0.51
PTK6 Q13882 2/20 0.51
PRKD2 Q9BZL6 2/20 0.51
MAPK10 P53779 2/20 0.46
ALDH1A1 P00352 2/20 0.46
PRKACA P17612 2/20 0.46
SLK Q9H2G2 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3064157 0.89 CYP3A4 (0.44) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL4697800 0.84 CYP3A4 (0.41) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL3792553 0.80 CYP11B1 (0.50) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL4696646 0.79 ADORA2B (0.41) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL3063770 0.78 ALDH1A1 (0.44) ALDH1A1KDM4ELMNACYP1A2CYP3A4
SCHEMBL15075635 0.77 MAPK14 (0.78) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL3054133 0.76 NPY5R (0.47) CYP3A4MAPTCYP2C19CYP11B1NPY5R
SCHEMBL3790745 0.74 CYP11B1 (0.48) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL11838228 0.73 KDM4E (0.50) MAPK14MAPK13GCGRMAPK12MAPK11
SCHEMBL2822605 0.72 NPY5R (0.55) MAPK14MAPK13GCGRMAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US claimed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US claimed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. 2010-10-28 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-7790728-B2 Pyrazine derivatives useful as adenosine receptor antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2010-09-07 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists LABORATORIOS ALMIRALL, S.A. (ES) 2009-02-12 US disclosed
EP-1922313-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS Laboratorios Almirall, S.A. (ES) 2008-05-21 EP disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed
WO-2007017096-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS LABORATORIOS ALMIRALL, S.A. (ES) 2007-02-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042891-A1 Pyrazine Derivatives Useful as Adenosine Receptor Antagonists ADORA2B, ADORA2A, ADORA3 MAPK14 3281/4885MAPK13 3097/4885GCGR 625/4885
US-20100273757-A1 PYRAZINE DERIVATIVES USEFUL AS ADENOSINE RECEPTOR ANTAGONISTS ADORA2B, ADORA2A, ADORA1 MAPK14 4099/4885MAPK13 3889/4885GCGR 384/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.